Efficacy and safety of dapagliflozin over 1 year as add-on to insulin therapy in Japanese patients with type 2 diabetes: the DAISY (Dapagliflozin Added to patients under InSulin therapY) trial-Reference-Cited by-同舟云学术

Efficacy and safety of dapagliflozin over 1 year as add-on to insulin therapy in Japanese patients with type 2 diabetes: the DAISY (Dapagliflozin Added to patients under InSulin therapY) trial

Published:2017-02-23 Issue:4 Volume:19 Page:562-570
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Araki Eiichi¹,Onishi Yukiko²,Asano Michiko³,Kim Hyosung³,Yajima Toshitaka³

Affiliation:

1. Department of Metabolic Medicine, Faculty of Life Sciences; Kumamoto University; Kumamoto Japan

2. Division of Diabetes and Metabolism, The Institute for Adult Diseases; Asahi Life Foundation; Tokyo Japan

3. Research and Development, AstraZeneca K.K.; Osaka Japan

Funder

AstraZeneca KK.

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.12853/fullpdf

Reference25 articles.

1. Secondary failure to treatment with oral antidiabetic agents in non-insulin-dependent diabetes;Groop;Diabetes Care,1986

2. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial;Heine;Ann Intern Med,2005

3. United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus;Turner;Ann Intern Med,1996

4. Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial;Kaku;Diabetes Obes Metab,2013

5. Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise;Kaku;Diabetes Obes Metab,2014

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Influence of Dapagliflozin Dosing on Low‐Density Lipoprotein Cholesterol in Type 2 Diabetes Mellitus: A Systematic Literature Review and Meta‐Analysis;The Journal of Clinical Pharmacology;2024-08

2. Effects of sodium-glucose cotransporter 2 inhibitors on bone metabolism in patients with type 2 diabetes mellitus: a systematic review and meta-analysis;BMC Endocrine Disorders;2024-04-24

3. Renal, cardiovascular, and safety outcomes of adding sodium–glucose cotransporter-2 inhibitors to insulin therapy in patients with type-2 diabetes: a meta-analysis;International Urology and Nephrology;2023-07-29

4. Risk of diabetic ketoacidosis of SGLT2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials;Frontiers in Pharmacology;2023-06-13

5. Efficacy and safety of empagliflozin in combination with insulin in Chinese patients with type 2 diabetes and insufficient glycaemic control: A phase III, randomized, double‐blind, placebo‐controlled, parallel study;Diabetes, Obesity and Metabolism;2023-03-23